190 related articles for article (PubMed ID: 33966446)
1. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
[TBL] [Abstract][Full Text] [Related]
2. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
[TBL] [Abstract][Full Text] [Related]
3. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH
Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
6. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
[TBL] [Abstract][Full Text] [Related]
8. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching.
Inoue K; Tsugawa Y; Mangione CM; Duru OK
PLoS Med; 2021 Jun; 18(6):e1003645. PubMed ID: 34061852
[TBL] [Abstract][Full Text] [Related]
9. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
[TBL] [Abstract][Full Text] [Related]
10. Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching.
Inoue K; Figueroa JF; Orav EJ; Tsugawa Y
J Epidemiol Community Health; 2020 Aug; 74(8):647-654. PubMed ID: 32350126
[TBL] [Abstract][Full Text] [Related]
11. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists).
Wong ND; Bang M; Block RC; Peterson ALH; Karalis DG
Am J Cardiol; 2021 Aug; 152():57-62. PubMed ID: 34147211
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
13. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
[TBL] [Abstract][Full Text] [Related]
14. Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Feng X; Berklein F; Rane PB; Habib M; Lin PJ
Cardiovasc Drugs Ther; 2021 Oct; 35(5):965-973. PubMed ID: 32594283
[TBL] [Abstract][Full Text] [Related]
15. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
Doshi JA; Puckett JT; Parmacek MS; Rader DJ
Circ Cardiovasc Qual Outcomes; 2018 Jan; 11(1):e003939. PubMed ID: 29326146
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical industry-sponsored meals are associated with increased prescriptions and Medicare spending for dupilumab among dermatologists in the United States.
Murayama A
J Eval Clin Pract; 2024 Apr; 30(3):435-439. PubMed ID: 38149692
[TBL] [Abstract][Full Text] [Related]
17. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
[TBL] [Abstract][Full Text] [Related]
18. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM
Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Davis LE; Pogge EK
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
[TBL] [Abstract][Full Text] [Related]
20. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
